Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 2.92 g/l; potassium chloride, quantity: 7.46 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 1.026 g (equivalent: vancomycin, qty 1 g) - injection, powder for - excipient ingredients: nitrogen; hydrochloric acid; water for injections - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 513 mg (equivalent: vancomycin, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; water for injections; nitrogen - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - micafungin sodium, quantity: 101.73 mg (equivalent: micafungin, qty 100 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide; lactose monohydrate - mycamine is indicated for: ? treatment of invasive candidiasis in children and adults ? treatment of oesophageal candidiasis in adults, adolescents greater than or equal to 16 years of age and the elderly patients for whom intravenous therapy is appropriate ? prophylaxis of candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - micafungin sodium, quantity: 50.86 mg (equivalent: micafungin, qty 50 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide; lactose monohydrate - mycamine is indicated for: ? treatment of invasive candidiasis in children and adults ? treatment of oesophageal candidiasis in adults, adolescents greater than or equal to 16 years of age and the elderly patients for whom intravenous therapy is appropriate ? prophylaxis of candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 6 mg/ml; calcium chloride dihydrate, quantity: 0.27 mg/ml; potassium chloride, quantity: 0.4 mg/ml; sodium lactate, quantity: 3.12 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solution may also be used as a solvent for intravenously administrated drugs where compatibility has been established. compound sodium lactate is particularly suitable for the replacement of extracellular fluid loss when isotonic dehydration is evident and in burn therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 6.24 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established. indications as at 22 august 2005 : compound sodium lactate solution is particularly suitable for replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - sodium lactate, quantity: 3.17 g/l; sodium chloride, quantity: 6 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - compound sodium lactate (hartmann's solution) injection is used for intrvenous fluid and electrolyte replacement, as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency, and as a vehicle for intravenous drug delivery, if the drugs are compatible with the solutions.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - sodium lactate, quantity: 3.17 g/l; sodium chloride, quantity: 6 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - compound sodium lactate (hartmann's solution) injection is used for intrvenous fluid and electrolyte replacement, as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency, and as a vehicle for intravenous drug delivery, if the drugs are compatible with the solutions.

Ireland - English - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium nitrite - solution for injection - 30 milligram(s)/millilitre - sodium nitrite